- Home
- SGHT vs ZURA Comparison
SGHT vs ZURA Comparison
Compare SGHT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- ZURA
- Stock Information
- Founded
- SGHT 2011
- ZURA 2022
- Country
- SGHT United States
- ZURA United States
- Employees
- SGHT N/A
- ZURA N/A
- Industry
- SGHT Medical Specialities
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGHT Health Care
- ZURA Health Care
- Exchange
- SGHT Nasdaq
- ZURA Nasdaq
- Market Cap
- SGHT 222.3M
- ZURA 69.9M
- IPO Year
- SGHT 2021
- ZURA N/A
- Fundamental
- Price
- SGHT $3.44
- ZURA $1.31
- Analyst Decision
- SGHT Buy
- ZURA Buy
- Analyst Count
- SGHT 8
- ZURA 7
- Target Price
- SGHT $4.01
- ZURA $14.33
- AVG Volume (30 Days)
- SGHT 162.1K
- ZURA 708.2K
- Earning Date
- SGHT 07-31-2025
- ZURA 08-08-2025
- Dividend Yield
- SGHT N/A
- ZURA N/A
- EPS Growth
- SGHT N/A
- ZURA N/A
- EPS
- SGHT N/A
- ZURA N/A
- Revenue
- SGHT $78,109,000.00
- ZURA N/A
- Revenue This Year
- SGHT N/A
- ZURA N/A
- Revenue Next Year
- SGHT $11.60
- ZURA N/A
- P/E Ratio
- SGHT N/A
- ZURA N/A
- Revenue Growth
- SGHT N/A
- ZURA N/A
- 52 Week Low
- SGHT $2.03
- ZURA $0.97
- 52 Week High
- SGHT $8.45
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- SGHT 37.27
- ZURA 59.63
- Support Level
- SGHT $3.36
- ZURA $1.00
- Resistance Level
- SGHT $4.33
- ZURA $1.45
- Average True Range (ATR)
- SGHT 0.26
- ZURA 0.10
- MACD
- SGHT -0.13
- ZURA 0.03
- Stochastic Oscillator
- SGHT 6.39
- ZURA 68.89
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.